# US 2024/0254131 A1 · Novel heterocyclic compounds, compositions, methods of preparation and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254131 A1
- Document ID: US20240254131A1
- Status: Published application
- Kind: A1
- Application number: 18/558,860
- Filed: 2022-05-05
- Published: 2024-08-01
- Earliest claimed: 2021-05-07
- Assignees: Organon R&D Finland Ltd.
- Applicants: Organon R&D Finland Ltd
- Inventors: Tero LINNANEN; Leena HIRVELÄ; Kaisa ILLIKAINEN; Marjo HAKOLA; Sanna NIINIVEHMAS; Olli PENTIKÄINEN; Camilla STJERNSCHANTZ
- Web page: https://patentgrep.com/patent/US20240254131A1

## CPC

- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 487/04: Ortho-condensed systems
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/497: containing further heterocyclic rings
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61P 35/00: Antineoplastic agents
- C07D 211/70: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 211/72: with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/14: containing three or more hetero rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/14: containing three or more hetero rings
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 471/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D 498/18: Bridged systems
- C07D 513/00: Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of formula (I) to salts, solvates and solvates of salts thereof, and to pharmaceutical compositions comprising these compounds as active ingredients. The invention further relates to their use as aldo-keto reductase family 1 C3 (AKR1C3), also known as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5, HSD17B5) and prostaglandin (PG) F2α synthase, inhibitors. The invention further relates to methods for their preparation, and to uses of said compounds.

## Claims

### Claim 1

A compound of formula (I)
wherein
R1 is a group selected from C1-6-alkyl, C1-6-haloalkyl, C1-6-perhaloalkyl, (CH2)mOR′, (CH2)mN(R′)2, 6- to 13-membered aryl, 5- to 11-membered heteroaryl, 3- to 12-membered cycloalkyl, and 3- to 10-membered heterocyclyl, and said group being optionally substituted with one to six substituent(s) each independently selected from R11;
R2 is a group selected from C1-6-alkyl, C1-6-haloalkyl, C1-6-perhaloalkyl, (CH2)mOR′, (CH2)mN(R′)2, 6- to 13-membered aryl, 5- to 11-membered heteroaryl, 3- to 12-membered cycloalkyl, and 3- to 10-membered heterocyclyl, and said group being optionally substituted with one to six substituent(s) each independently selected from R12;
or
R1 and R2, together with the ring nitrogen atom they are attached to, form a 4- to 11-membered unsaturated or aromatic heterocycle or a 4- to 10-membered saturated or partially unsaturated heterocycle, and said heterocycle being optionally substituted with one to six substituent(s) each independently selected from R13;
R3 is a group selected from 6- to 13-membered aryl, 5- to 11-membered heteroaryl, 3- to 12-membered cycloalkyl, and 3- to 10-membered heterocyclyl, and said group being optionally substituted with one to six substituent(s) each independently selected from R31;
R11 is selected from halogen, CN, C1-6-alkyl, C1-6-alkoxy, C1-6-(per)haloalkyl, C1-6-(per)haloalkoxy, OR′, oxo, (OCH2)nOR′, SR′, NO2, N(R′)2, (CH2)nN(R′)2, (CH2)nOR′, CH(XR′)R′, CO2R′, C(O)N(R′)2, C(O)NR′C(O)R″, NR′COR″, C(═NH)R″, C(═N—OR′)R″, C(O)R″, NR′C(O)NR″, NR′SO2R″, SO2NHSO2R″, and SO2N(R′)2 and being optionally substituted with one or more substituents each independently selected from the group consisting of R′, OR′, N(R′)2;
R12 is selected from halogen, CN, C1-6-alkyl, C1-6-alkoxy, C1-6-(per)haloalkyl, C1-6-(per)haloalkoxy, OR′, oxo, (OCH2)nOR′, SR′, NO2, N(R′)2, (CH2)nN(R′)2, (CH2)nOR′, CH(XR′)R′, CO2R′, C(O)N(R′)2, NHCOR″, C(═NH)R″, C(═N—OR′)R″, C(O)R″, and SO2N(R′)2 and being optionally substituted with one or more substituents each independently selected from the group consisting of R′, OR′, N(R′)2;
R13 is selected from halogen, CN, C1-6-alkyl, C1-6-alkoxy, C1-6-(per)haloalkyl, C1-6-(per)haloalkoxy, OR′, oxo, (OCH2)nOR′, SR′, NO2, N(R′)2, (CH2)nN(R′)2, (CH2)nOR′, CH(XR′)R′, CO2R′, C(O)N(R′)2, C(O)NR′C(O)R″, NR′C(O)R″, C(═NH)R″, C(═N—OR′)R″, C(O)R″, NR′C(O)NR″, NR′SO2R″, SO2NHSO2R″, and SO2N(R′)2 and being optionally substituted with one or more substituents each independently selected from the group consisting of R′, OR′, N(R′)2;
R31 is selected from halogen, CN, C1-6-alkyl, C1-6-alkoxy, C1-6-(per)haloalkyl, C1-6-(per)haloalkoxy, OR′, oxo, (OCH2)nOR′, SR′, NO2, N(R′)2, (CH2)nN(R′)2, (CH2)nOR′, CO2R′, C(O)N(R′)2, C(O)NR′C(O)R″, NR′C(O)R″, C(═NH)R″, C(═N—OR′H)R″, C(O)R″, NR′C(O)NR″, NR′SO2R″, SO2NHSO2R″, and SO2N(R′)2 and being optionally substituted with one or more substituents each independently selected from the group consisting of R′, OR′, N(R′)2;
each R′ is independently selected from H, C1-6-alkyl, C1-6-haloalkyl, and C1-6-perhaloalkyl, or when part of any N(R′)2 both R′s, together with the nitrogen they are attached to, may form a 3- to 6-membered aliphatic or aromatic heterocyclic ring comprising 1 to 4 heteroatoms each independently selected from N, S, and O;
each R″ is independently selected from C1-6-alkyl, C1-6-haloalkyl, and C1-6-perhaloalkyl;
X is O or S;
m is 0-6; and
n is 1-6; or
a salt, solvate or solvate of a salt thereof.

### Claim 2 (depends on 1)

A compound as claimed in any preceding claim, wherein
R3 is a group selected from 6-membered aryl and 5- to 9-membered heteroaryl, wherein the heteroaryl comprises 1 to 3 heteroatom(s) each independently selected from the group consisting of N, O, and S, and said group being optionally substituted with one to three substituent(s) each independently selected from R31;
R31 is as defined in claim 1; or
a salt, solvate or solvate of a salt thereof.

### Claim 3 (depends on 1)

A compound as claimed in claim 1, wherein R1 is a group selected from C1-6-alkyl, 5- to 9-membered heteroaryl, and 5- to 7-membered heterocyclyl, and said group being optionally substituted with one to three substituent(s) each independently selected from R11; and
R2 is a group selected from C1-6-alkyl, 5- to 9-membered heteroaryl, and 5- to 7-membered heterocyclyl, and said group being optionally substituted with one to three substituent(s) each independently selected from R12;
R11 and R12 are as defined in claim 1; or
a salt, solvate or solvate of a salt thereof.

### Claim 4 (depends on 1)

A compound as claimed in claim 1, wherein
R1 and R2, together with the ring nitrogen atom to which they are attached, form a 5- to 9-membered aromatic heterocycle or a 4- to 9-membered saturated heterocycle, wherein the heterocycle optionally comprises 1 to 4 further heteroatom(s) each independently selected from the group consisting of N, O, and S, and said heterocycle being optionally substituted with one to four substituent(s) each independently selected from R13;
R13 is as defined in claim 1; or
a salt, solvate or solvate of a salt thereof.

### Claim 5 (depends on 1)

A compound as claimed in claim 1, wherein
R3 is a group selected from phenyl, pyridinyl, thienyl, and 1H-indazolyl, and said group being optionally substituted with one or two substituent(s) each independently selected from R31;
R31 is as defined in claim 1; or
a salt, solvate or solvate of a salt thereof.

### Claim 6 (depends on 1)

A compound as claimed in claim 1, wherein
R31 is selected from halogen, C1-3-alkyl, C1-3-(per)haloalkyl, C1-3-(per)haloalkoxy, and C(O)C1-6-alkyl; or a salt, solvate or solvate of a salt thereof.

### Claim 7 (depends on 1)

A compound as claimed in claim 1, wherein
R1 is a group selected from methyl, ethyl, and tetrahydropyranyl;
R2 is a group selected from methyl, ethyl, and tetrahydropyranyl; or
a salt, solvate or solvate of a salt thereof.

### Claim 8 (depends on 1)

A compound as claimed in claim 1, wherein
R1 and R2, together with the ring nitrogen atom to which they are attached, form an aromatic heterocycle or a saturated heterocycle selected from piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, indolinyl, isoindolinyl, 4,5-dihydro-7H-isoxazolo[3,4-c]pyridinyl, 6,7-dihydro-4H-isoxazolo[4,3-c]pyridinyl, 6,7-dihydro-4H-[1,2,3]triazolo[1,5-a]pyrazinyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, azetidinyl, 1,4,6,7-tetrahydroimidazo[4,5-c]pyridinyl, 1,4,6,7-tetrahydropyrazolo[4,3-c]pyridinyl, 5,6-dihydro-8H-[1,2,4]triazolo[1,5-a]pyrazinyl, 5,6-dihydro-8H-imidazo[1,5-a]pyrazinyl, 3,4-dihydro-1H-pyrrolo[1,2-a]pyrazinyl, 2,3-dihydropyrrolo[2,3-b]pyridinyl, 2-azabicyclo[2.2.1]heptanyl, 6,7-dihydro-4H-thieno[3,2-c]pyridinyl, thiomorpholinyl, octahydrocyclopenta[c]pyrrolyl, N-methyl-N-(oxetan-3-yl), 4-hydroxyazepanyl, 5-fluoroindolinyl, 2-methylpiperidinyl, 4-isopropoxypiperidinyl, 4-propoxypiperidinyl, and 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazinyl, and said heterocycle being optionally substituted with one or two substituent(s) each independently selected from R13;
R13 is as defined in claim 1; or
a salt, solvate or solvate of a salt thereof.

### Claim 9 (depends on 1)

A compound as claimed in claim 1, wherein
R13 is selected from CN, C1-3-(per)haloalkyl, OR′, (CH2)nOR′, CH(OH)C1-6-alkyl, C(O)R″, and SO2N(R′)2;
each R′ is independently selected from H, and C1-6-alkyl;
each R″ is independently selected from C1-6-alkyl;
n is 1-3; or
a salt, solvate or solvate of a salt thereof.

### Claim 10 (depends on 1)

A compound as claimed in claim 1, wherein the compound has formula (Ia)
wherein
Y is N or C—R4, wherein R4 is H or F;
R5 is H, C1, or F;
or
Y is C—R4, and R4 and R5, together with the carbon atoms they are attached to, form a 5-membered aromatic heterocycle;
R6 is F, Cl, or H;
or
Y is N or C—R4, wherein R4 is H or F;
R5 and R6, together with the carbon atoms they are attached to, form a 5-membered aromatic heterocycle; and
R1 and R2 are as defined in claim 1; or
a salt, solvate or solvate of a salt thereof.

### Claim 11 (depends on 1)

A compound as claimed in claim 1, wherein
R1 and R2, together with the ring nitrogen atom to which they are attached, form an aromatic heterocycle or a saturated heterocycle selected from piperidin-1-yl, piperazin-1-yl, morpholin-4-yl, pyrrolidin-1-yl, indolin-1-yl, isoindolin-2-yl, 4,5-dihydro-7H-isoxazolo[3,4-c]pyridin-6-yl, 6,7-dihydro-4H-isoxazolo[4,3-c]pyridin-5-yl, 6,7-dihydro-4H-[1,2,3]triazolo[1,5-a]pyrazin-5-yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, azetidin-1-yl, 1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl, 1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl, 5,6-dihydro-8H-[1,2,4]triazolo[1,5-a]pyrazin-7-yl, 5,6-dihydro-8H-imidazo[1,5-a]pyrazin-7-yl, 3,4-dihydro-1H-pyrrolo[1,2-a]pyrazin-2-yl, 2,3-dihydropyrrolo[2,3-b]pyridin-1-yl, 2-azabicyclo[2.2.1]heptan-2-yl, 6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl, and 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl, and said heterocycle being optionally substituted with one or two substituent(s) each independently selected from R13;
R13 is selected from CN, C1-3-(per)haloalkyl, OR′, (CH2)nOR′, CH(OH)C1-6-alkyl, C(O)R″, and SO2N(R′)2;
each R′ is independently selected from H, and C1-6-alkyl;
each R″ is independently selected from C1-6-alkyl; or
a salt, solvate or solvate of a salt thereof.

### Claim 12 (depends on 1)

A compound as claimed in claim 1, wherein the compound has formula (Ib) or (Ic)
wherein
D is C or N;
E is N, NH, or CH;
F is O or N;
Y is N or C—R4, wherein R4 is H or F;
R5 is H, Cl, or F;
or
Y is C—R4, and R4 and R5, together with the carbon atoms they are attached to, form a 5-membered aromatic heterocycle;
R6 is F, Cl, or H;
or
Y is N or C—R4, wherein R4 is H or F;
R5 and R6, together with the carbon atoms they are attached to, form a 5-membered aromatic heterocycle; and
R7 is OH or CH2OH; or
a salt, solvate or solvate of a salt thereof.

### Claim 13

A compound, selected from the group consisting of:
2-(4-fluorophenyl)-2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (4);
2-(4-fluorophenyl)-2-(1-(4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (12);
2-(4-fluorophenyl)-2-(1-(4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyrazine-5-carbonyl)piperidin-4-ylidene)acetonitrile (13);
2-(4-chlorophenyl)-2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (18);
2-(4-fluorophenyl)-2-(1-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (25);
2-(3,4-difluorophenyl)-2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (41);
2-(2,4-difluorophenyl)-2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (42);
2-(3,4-difluorophenyl)-2-(1-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (43);
2-(3,4-difluorophenyl)-2-(1-(5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-7-carbonyl)piperidin-4-ylidene)acetonitrile (44);
2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)-2-(1H-indazol-4-yl)acetonitrile (48);
2-(5-chloropyridin-2-yl)-2-(1-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (67);
2-(4-chlorophenyl)-2-(1-(4-(hydroxymethyl)piperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (74);
2-(3-chlorophenyl)-2-(1-(4-hydroxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (80);
2-(5-fluoropyridin-2-yl)-2-(1-(4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (84);
1-(4-((3-chlorophenyl)(cyano)methylene)piperidine-1-carbonyl)piperidine-4-sulfonamide (99);
2-(4-chlorophenyl)-2-(1-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (113);
2-(1-(4-(hydroxymethyl)piperidine-1-carbonyl)piperidin-4-ylidene)-2-(1-methyl-1H-indazol-7-yl)acetonitrile (118);
2-(1H-indazol-4-yl)-2-(1-(4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (138);
2-(3-chlorophenyl)-2-(1-(4-(2-hydroxyethyl)piperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (140);
2-(4-chlorophenyl)-2-(1-(4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (141);
2-(1H-indazol-4-yl)-2-(1-(4-methoxypiperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (144);
2-(1H-indazol-4-yl)-2-(1-(4-(trifluoromethyl)piperidine-1-carbonyl)piperidin-4-ylidene)acetonitrile (145);
2-(1-(3-oxa-8-azabicyclo[3.2.1]octane-8-carbonyl)piperidin-4-ylidene)-2-(3-chlorophenyl)acetonitrile (156);
2-(5-chloropyridin-2-yl)-2-(1-(4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-5-carbonyl)piperidin-4-ylidene)acetonitrile (161); or
a salt, solvate or solvate of a salt thereof.

### Claim 14 (depends on 1)

A method for the preparation of a compound of formula (I), or a salt, solvate or solvate of a salt thereof, as defined in claim 1, comprising the steps:
reacting a compound of formula (II)
wherein the dotted line represents an optional bond,
R7 is a leaving group A or absent when the dotted line represents a bond, and
R3A is R3 as defined for compound of formula (I) or a leaving group B, with a compound of formula (III)
or hydrogen halide thereof, wherein
R1 and R2 are as defined for compound of formula (I);
or
reacting a compound of formula (IV)
or hydrogen halide thereof, wherein
R3A is R3 as defined for compound of formula (I) or a leaving group B,
with a compound of formula (V)
wherein the dotted line represents an optional bond,
R7 is a leaving group A or absent when the dotted line represents a bond, and
R1 and R2 are as defined for compound of formula (I);
optionally in the presence of a base,
to obtain a compound of formula (I)
wherein
R1, R2, and R3 are as defined for compound of formula (I);
or
R1 and R2 are as defined for compound of formula (I), and R3 is the leaving group B; and optionally, provided that R3 is the leaving group B, reacting the obtained compound of formula (I) with a compound of formula (VII)
wherein
R3B is R3 as defined for compound of formula (I),
Z is a leaving group C or B(R8)2, wherein
R8 is OH, OC1-6-alkyl, or both R8, together with the ring boron atom they are attached to, form a cyclic boronic ester,
in the presence of a base and a coupling agent,
to obtain a compound of formula (I), wherein R1, R2, and R3 are as defined in any preceding claim;
and optionally converting the compound of formula (I) to a salt, solvate or solvate of a salt thereof.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising an effective amount of one or more compounds of formula (I), or a salt, solvate, or solvate of a salt thereof, as claimed in claim 1, together with one or more pharmaceutically acceptable excipient(s).

### Claim 16 (depends on 1, 14)

The pharmaceutical composition as claimed in claim 14 comprising one or more compounds as claimed in claim 1 in combination with one or more further active ingredients.

### Claim 17 (depends on 1)

A compound, or a salt, solvate or solvate of a salt thereof, as claimed in claim 1 for use as a medicament.

### Claim 18 (depends on 1)

A method of treating a disease or disorder, comprising administering a compound, or a salt, or a solvate, or solvate of a salt thereof, as claimed in claim 1, wherein the disease or disorder is selected from the group consisting of polycystic ovary syndrome, endometriosis, uterine leiomyoma, uterine bleeding disorders, dysmenorrhoea, hyperandrogenism, chronic obstructive pulmonary disease (COPD), lung cancer, non-small-cell lung cancer, prostate cancer including castration-resistant prostate cancer, prostate hyperplasia, breast cancer, invasive breast ductal carcinoma, triple negative breast cancer, endometrial carcinoma, renal cell carcinoma, bladder carcinoma, pancreatic adenocarcinoma, acute myeloid leukemia, T-Cell acute lymphoblastic leukemia, melanoma, non-Hodgkins lymphoma, acne, seborrhoea, hair loss, premature sexual maturity, obesity, and inflammation-related pain.

### Claim 19 (depends on 13)

A pharmaceutical composition comprising an effective amount of one or more compounds of claim 13, or a salt, solvate, or solvate of a salt thereof, together with one or more pharmaceutically acceptable excipient(s).

### Claim 20 (depends on 19)

A method of treating a disease or disorder, comprising administering a pharmaceutical composition of claim 19, wherein the disease or disorder is selected from the group consisting of polycystic ovary syndrome, endometriosis, uterine leiomyoma, uterine bleeding disorders, dysmenorrhoea, hyperandrogenism, chronic obstructive pulmonary disease (COPD), lung cancer, non-small-cell lung cancer, prostate cancer including castration-resistant prostate cancer, prostate hyperplasia, breast cancer, invasive breast ductal carcinoma, triple negative breast cancer, endometrial carcinoma, renal cell carcinoma, bladder carcinoma, pancreatic adenocarcinoma, acute myeloid leukemia, T-Cell acute lymphoblastic leukemia, melanoma, non-Hodgkins lymphoma, acne, seborrhoea, hair loss, premature sexual maturity, obesity, and inflammation-related pain.
